Author

Kuzhuvelil B. Harikumar

Rajiv Gandhi Centre for BiotechnologyORCID 0000-0002-1763-4179Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Organism:mouse· 2 Approach:Bayesian inference· 1 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1

Frequent Co-Authors

Arun (Geetha) ViswanathaniD· 3 shared Chenicheri Kizhakkeveettil KeerthanaiD· 3 shared Kalimuthu Kalishwaralal· 3 shared Lekshmi R. NathiD· 3 shared Mundanattu SwethaiD· 3 shared Nikhil Ponnoor AntoiD· 3 shared Noah IsakoviD· 3 shared Ravi Shankar LankalapalliiD· 3 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Arun (Geetha) ViswanathanORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 3, 2026

Overweight status drives early tumor microenvironment reprogramming in pancreatic ductal adenocarcinoma: a cell-type-resolved Bayesian hierarchical modeling and interactome analysis

Arun (Geetha) Viswanathan, Justin Seby, Kuzhuvelil B. Harikumar

This study identifies how overweight status reprograms the pancreatic tumor microenvironment through cell-type-specific changes using Bayesian modeling and interactome analysis.

DOI 10.64898/2026.05.14.721695

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCell Death DiscoveryPeer-reviewedApr 16, 2026

Uttroside B, a US FDA-designated Orphan drug, mitigates thedevelopment of hepatocellular carcinoma and its pulmonary metastasis via EGFR/ERK-mediated inhibition of SREBP-1 and STAT-3

Chenicheri Kizhakkeveettil Keerthana, Tennyson Prakash Rayginia, Kalimuthu Kalishwaralal…·Ruby John Anto

This study shows that Uttroside B inhibits hepatocellular carcinoma and its pulmonary metastasis by blocking the EGFR/ERK pathway and its downstream targets SREBP-1 and STAT-3.

1 citation

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 8, 2025

Evaluating the therapeutic efficacy of the US FDA-designated Orphan drug, uttroside B in impeding hepatocarcinogenesis via induction of immunogenic apoptosis, using a murine model of Aflatoxin B1-induced liver carcinogenesis

Mundanattu Swetha, Chenicheri Kizhakkeveettil Keerthana, Tennyson Prakash Rayginia…·Ruby John Anto

This study evaluates uttroside B's efficacy in preventing AFB1-induced hepatocarcinogenesis in mice by inducing immunogenic apoptosis and blocking immune checkpoints.

DOI 10.1101/2025.09.08.674785

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintNov 6, 2024

Uttroside B, a US-FDA-Designated Orphan Drug Against Hepatocellular Carcinoma (HCC), Impedes Non-alcoholic Steatohepatitis (NASH) and NASH -Induced HCC

Tennyson Prakash Rayginia, Chenicheri Kizhakkeveettil Keerthana, Sreekumar Usha Devi Aiswarya…·Ruby John Anto

This study demonstrates that Uttroside B alleviates NASH and prevents its progression to HCC in mouse models.

DOI 10.1101/2024.11.06.622394

mouseexperimental assay

𝕏 PostBluesky